New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Rescigno, P ^a   Cerillo, I ^a   Ruocco, R ^a   Condello, C ^a   De Placido, S ^a   Pensabene, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLIN E; DALANTERCEPT; DOXORUBICIN; ENDOPLASMIC RETICULUM GOLGI INTERMEDIATE COMPARTMENT PROTEIN 53; EVEROLIMUS; FLAVOPIRIDOL; LAPATINIB; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MARGETUXIMAB; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NINTEDANIB; OLAPARIB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RECOMBINANT ENDOSTATIN; ROSCOVITINE; RUCAPARIB; SORAFENIB; TEMSIROLIMUS; TRABECTEDIN; TRASTUZUMAB; VASCULOTROPIN; VELIPARIB; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CHROMATIN STRUCTURE; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONSENSUS; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA HELIX; DNA METHYLATION; ENDOMETRIOSIS; FEMALE; GENE AMPLIFICATION; GENETIC RISK; GENETIC STABILITY; GENETIC TRANSCRIPTION; HUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SURVIVAL; UTERINE TUBE; BIOLOGICAL MODEL; EARLY DIAGNOSIS; OVARIAN NEOPLASMS; PROGNOSIS; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84884263331     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/852839     Document Type: Review

References (92)

1. GLOBOCAN 2008 v1.2. Cancer Incidence and Mortality Worldwide 2010 Lyon, France IARC Press IARC CancerBase, no. 10. http://globocan.iarc.fr/
2. Heintz A. P., Odicino F., Maisonneuve P., Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. International Journal of Gynaecology and Obstetrics 2006 95 supplement 1 S161 S192 10.1016/S0020-7292(06)60033-7
3. Colombo N., Guthrie D., Chiari S., Parmar M., Qian W., Swart A. M., Torri V., Williams C., Lissoni A., Bonazzi C., International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. Journal of the National Cancer Institute 2003 95 2 125 132 2-s2.0-0037440317
4. Piccart M. J., Bertelsen K., James K., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Journal of the National Cancer Institute 2000 92 9 699 708 2-s2.0-0034612772
5. Burger R. A., Brady M. F., Bookman M. A., Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine 2011 365 2473 2483
6. Perren T. J., Swart A. M., Pfisterer J., A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine 2011 365 26 2484 2496 10.1056/NEJMoa1103799
7. Kurman R. J., Shih I.-M., Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Human Pathology 2011 42 7 918 931 2-s2.0-79959328816 10.1016/j.humpath.2011.03.003
8. Prat J., Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv 2012 460 3 237 249 2-s2.0-84860336909 10.1007/s00428-012-1203-5
9. Lee K. R., Tavassoli F. A., Prat J., Tavassoli F. A., Devilee P., Tumours of the ovary and peritoneum: surface epithelial-stromal tumours. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003 chapter 2 Lyon, France IARC Press 117 145
10. Ahmed A. A., Etemadmoghadam D., Temple J., Lynch A. G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., DeFazio A., Bowtell D., Brenton J. D., Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology 2010 221 1 49 56 2-s2.0-77950965840 10.1002/path.2696
11. Senturk E., Cohen S., Dottino P. R., Martignetti J. A., A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecologic Oncology 2010 119 2 376 383 2-s2.0-77957749830 10.1016/j.ygyno.2010.07.026
12. Kurman R. J., Shih I.-M., The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 2010 34 3 433 443 2-s2.0-77649219639 10.1097/PAS.0b013e3181cf3d79
13. Piek J. M. J., van Diest P. J., Zweemer R. P., Jansen J. W., Poort-Keesom R. J. J., Menko F. H., Gille J. J. P., Jongsma A. P. M., Pals G., Kenemans P., Verheijen R. H. M., Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Journal of Pathology 2001 195 4 451 456 2-s2.0-0035175430 10.1002/path.1000
14. Chêne G., Penault-Llorca F., le Bouëdec G., Mishellany F., Dauplat M.-M., Jaffeux P., Aublet-Cuvelier B., Pouly J. L., Déchelotte P., Dauplat J., Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. International Journal of Gynecological Cancer 2009 19 1 65 72 2-s2.0-65649115078 10.1111/IGC.0b013e3181990127
15. Piek J. M. J., Verheijen R. H. M., Kenemans P., Massuger L. F., Bulten H., van Diest P. J., BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecologic Oncology 2003 90 2 491 2-s2.0-0043125582 10.1016/S0090-8258(03)00365-2
16. Callahan M. J., Crum C. P., Medeiros F., Kindelberger D. W., Elvin J. A., Garber J. E., Feltmate C. M., Berkowitz R. S., Muto M. G., Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. Journal of Clinical Oncology 2007 25 25 3985 3990 2-s2.0-34548525798 10.1200/JCO.2007.12.2622
17. Kindelberger D. W., Lee Y., Miron A., Hirsch M. S., Feltmate C., Medeiros F., Callahan M. J., Garner E. O., Gordon R. W., Birch C., Berkowitz R. S., Muto M. G., Crum C. P., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. American Journal of Surgical Pathology 2007 31 2 161 169 2-s2.0-33846624310 10.1097/01.pas.0000213335.40358. 47
18. Wiegand K. C., Shah S. P., Al-Agha O. M., ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England Journal of Medicine 2010 363 16 1532 1543 10.1056/NEJMoa1008433
19. Carcangiu M. L., Radice P., Manoukian S., Spatti G., Gobbo M., Pensotti V., Crucianelli R., Pasini B., Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. International Journal of Gynecological Pathology 2004 23 1 35 40 2-s2.0-0346251021 10.1097/01.pgp.0000101082.35393.84
20. Medeiros F., Muto M. G., Lee Y., Elvin J. A., Callahan M. J., Feltmate C., Garber J. E., Cramer D. W., Crum C. P., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. American Journal of Surgical Pathology 2006 30 2 230 236 2-s2.0-33645225423 10.1097/01.pas.0000180854.28831.77
21. Lee Y., Miron A., Drapkin R., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. The Journal of Pathology 2007 211 1 26 35 10.1002/path.2091
22. Veras E., Mao T.-L., Ayhan A., Ueda S., Lai H., Hayran M., Shih I.-M., Kurman R. J., Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. American Journal of Surgical Pathology 2009 33 6 844 853 2-s2.0-67549148930 10.1097/PAS.0b013e31819c4271
23. Bulun S. E., Endometriosis. The New England Journal of Medicine 2009 360 3 268 279 2-s2.0-58349090850 10.1056/NEJMra0804690
24. Hennessy B. T., Coleman R. L., Markman M., Ovarian cancer. The Lancet 2009 374 9698 1371 1382 2-s2.0-70349847555 10.1016/S0140-6736(09)61338-6
25. FIGO annual report, vol. 24. The Journal of Epidemiology and Biostatistics 2001 6 107 138
26. Gilks C. B., Ionescu D. N., Kalloger S. E., Köbel M., Irving J., Clarke B., Santos J., Le N., Moravan V., Swenerton K., Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology 2008 39 8 1239 1251 2-s2.0-47749086997 10.1016/j.humpath.2008.01.003
27. Bamias A., Sotiropoulou M., Zagouri F., Trachana P., Sakellariou K., Kostouros E., Kakoyianni K., Rodolakis A., Vlahos G., Haidopoulos D., Thomakos N., Antsaklis A., Dimopoulos M. A., Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. European Journal of Cancer 2012 48 10 1476 1483 2-s2.0-80054967314 10.1016/j.ejca.2011.09.023
28. Köbel M., Kalloger S. E., Baker P. M., Ewanowich C. A., Arseneau J., Zherebitskiy V., Abdulkarim S., Leung S., Duggan M. A., Fontaine D., Parker R., Huntsman D. G., Gilks C. B., Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. American Journal of Surgical Pathology 2010 34 7 984 993 2-s2.0-77954213625 10.1097/PAS.0b013e3181e1a3bb
29. Zaino R. J., Brady M. F., Lele S. M., Michael H., Greer B., Bookman M. A., Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal. Cancer 2011 117 3 554 562 2-s2.0-79251498945 10.1002/cncr.25460
30. Alexandre J., Ray-Coquard I., Selle F., Floquet A., Cottu P., Weber B., Falandry C., Lebrun D., Pujade-Lauraine E., Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Annals of Oncology 2010 21 12 2377 2381 2-s2.0-78649486193 10.1093/annonc/mdq257
31. Zaino R. J., Brady M. F., Lele S. M., Michael H., Greer B., Bookman M. A., Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011 117 3 554 562 2-s2.0-79251498945 10.1002/cncr.25460
32. Ayhan A., Kurman R. J., Yemelyanova A., Vang R., Logani S., Seidman J. D., Shih I.-M., Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. American Journal of Surgical Pathology 2009 33 8 1220 1224 2-s2.0-68249129961 10.1097/PAS.0b013e3181a24354
33. le Page C., Huntsman D. G., Provencher D. M., Mes-Masson A.-M., Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers 2010 2 2 913 954 2-s2.0-79952264074 10.3390/cancers2020913
34. Milde-Langosch K., Riethdorf S., Role of cell-cycle regulatory proteins in gynecological cancer. Journal of Cellular Physiology 2003 196 2 224 244 2-s2.0-0038121804 10.1002/jcp.10286
35. Green J. A., Berns E. M., Coens C., van Luijk I., Thompson-Hehir J., van Diest P., Verheijen R. H. M., van de Vijver M., van Dam P., Kenter G. G., Tjalma W., Ewing P. C., Teodorovic I., Vergote I., van der Burg M. E. L., Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer 2006 42 15 2539 2548 2-s2.0-33748959684 10.1016/j.ejca.2006. 06.015
36. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 2011 474 609 615 10.1038/nature10166
37. Bali A., O'Brien P. M., Edwards L. S., Sutherland R. L., Hacker N. F., Henshall S. M., Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clinical Cancer Research 2004 10 15 5168 5177 2-s2.0-4143107930 10.1158/1078-0432.CCR-03-0751
38. Geisler H. E., Geisler J. P., Miller G. A., p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 2001 92 4 781 786
39. Schmider-Ross A., Pirsig O., Gottschalk E., Denkert C., Lichtenegger W., Reles A., Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. Journal of Cancer Research and Clinical Oncology 2006 132 3 163 170 2-s2.0-29544433147 10.1007/s00432-005-0057-5
40. Skirnisdottir I., Seidal T., Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer. Cancer Genomic and Proteomics 2013 10 27 34
41. Verri E., Guglielmini P., Puntoni M., Perdelli L., Papadia A., Lorenzi P., Rubagotti A., Ragni N., Boccardo F., HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance: clinical study. Oncology 2005 68 2-3 154 161 2-s2.0-23844485690 10.1159/000086958
42. Hillig T., Thode J., Breinholt M. F., Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer. APMIS 2012 120 1000 1007 10.1111/j.1600-0463.2012.02929.x
43. Nakayama N., Nakayama K., Shamima Y., Ishikawa M., Katagiri A., Iida K., Miyazaki K., Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010 116 11 2621 2634 2-s2.0-77952835103 10.1002/cncr.24987
44. Venkitaraman A. R., Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002 108 2 171 182 2-s2.0-0037169354 10.1016/S0092-8674(02)00615-3
45. Chen S., Parmigiani G., Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007 25 11 1329 1333 2-s2.0-34248170114 10.1200/JCO.2006.09.1066
46. Antoniou A., Pharoah P. D. P., Narod S., Risch H. A., Eyfjord J. E., Hopper J. L., Loman N., Olsson H., Johannsson O., Borg Å., Pasini B., Radice P., Manoukian S., Eccles D. M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjäkoski K., Kallioniemi O.-P., Thompson D., Evans C., Peto J., Lalloo F., Evans D. G., Easton D. F., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 2003 72 5 1117 1130 2-s2.0-0038744296 10.1086/375033
47. Press J. Z., de Luca A., Boyd N., Young S., Troussard A., Ridge Y., Kaurah P., Kalloger S. E., Blood K. A., Smith M., Spellman P. T., Wang Y., Miller D. M., Horsman D., Faham M., Gilks C. B., Gray J., Huntsman D. G., Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008 8 article 17 2-s2.0-39549091276 10.1186/1471-2407-8-17
48. Norquist B. M., Garcia R. L., Allison K. H., Jokinen C. H., Kernochan L. E., Pizzi C. C., Barrow B. J., Goff B. A., Swisher E. M., The molecular pathogenesis of hereditary ovarian carcinoma. Cancer 2010 116 22 5261 5271 2-s2.0-77958488424 10.1002/cncr.25439
49. Wang Z., Wang F., Tang T., Guo C., The role of PARP1 in DNA damage response and its application in tumor therapy. Frontiers of Medicine 2012 6 2 156 164 10.1007/s11684-012-0197-3
50. Weil M. K., Chen A. P., PARP inhibitor treatment in ovarian and breast cancer. Current Problems in Cancer 2011 35 1 7 50 2-s2.0-79551587725 10.1016/j.currproblcancer.2010.12.002
51. Schubbert S., Shannon K., Bollag G., Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer 2007 7 4 295 308 2-s2.0-33947594129 10.1038/nrc2109
52. Vereczkey I., Serester O., Dobos J., Gallai M., Szakács O., Szentirmay Z., Tóth E., Molecular characterization of 103 ovarian serous and mucinous tumors. Pathology and Oncology Research 2011 17 3 551 559 2-s2.0-80052736732 10.1007/s12253-010-9345-8
53. Hanrahan A. J., Schultz N., Westfal M. L., Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discovery 2012 2 56 67 10.1158/2159-8290.CD-11-0170
54. Johnson S. M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K. L., Brown D., Slack F. J., RAS is regulated by the let-7 microRNA family. Cell 2005 120 5 635 647 2-s2.0-20044395613 10.1016/j.cell.2005.01.014
55. Caiola E., Rulli E., Fruscio R., Buda A., Broggini M., Marabese M., KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. American Journal of Cancer Research 2012 2 3 298 308
56. Levine D. A., Bogomolniy F., Yee C. J., Lash A., Barakat R. R., Borgen P. I., Boyd J., Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clinical Cancer Research 2005 11 8 2875 2878 2-s2.0-17144382038 10.1158/1078-0432.CCR-04-2142
57. Ihle N. T., Lemos R. Jr., Wipf P., Yacoub A., Mitchell C., Siwak D., Mills G. B., Dent P., Kirkpatrick D. L., Powis G., Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic ras is a dominant predictor for resistance. Cancer Research 2009 69 1 143 150 2-s2.0-58249120506 10.1158/0008-5472.CAN-07- 6656
58. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., Sasazuki T., Shirasawa S., Geuna M., Frattini M., Baselga J., Gallicchio M., Biffo S., Bardelli A., Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation 2010 120 8 2858 2866 2-s2.0-77955288855 10.1172/JCI37539
59. Janku F., Wheler J. J., Westin S. N., Moulder S. L., Naing A., Tsimberidou A. M., Fu S., Falchook G. S., Hong D. S., Garrido-Laguna I., Luthra R., Lee J. J., Lu K. H., Kurzrock R., PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of Clinical Oncology 2012 30 8 777 782 2-s2.0-84858855831 10.1200/JCO.2011.36.1196
60. Wong K.-K., Tsang Y. T. M., Deavers M. T., Mok S. C., Zu Z., Sun C., Malpica A., Wolf J. K., Lu K. H., Gershenson D. M., BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. American Journal of Pathology 2010 177 4 1611 1617 2-s2.0-77957354624 10.2353/ajpath.2010.100212
61. Gershenson D. M., Sun C. C., Bodurka D., Coleman R. L., Lu K. H., Sood A. K., Deavers M., Malpica A. L., Kavanagh J. J., Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecologic Oncology 2009 114 1 48 52 2-s2.0-67349236109 10.1016/j.ygyno.2009.03.001
62. Joseph E. W., Pratilas C. A., Poulikakos P. I., Tadi M., Wang W., Taylor B. S., Halilovic E., Persaud Y., Xing F., Viale A., Tsai J., Chapman P. B., Bollag G., Solit D. B., Rosen N., The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America 2010 107 33 14903 14908 2-s2.0-77957089182 10.1073/pnas.1008990107
63. Farley J., Brady W. E., Vathipadiekal V., Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. The Lancet Oncology 2013 14 2 134 140 10.1016/S1470-2045(12)70572-7
64. Grisham R. N., Iyer G., Garg K., BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013 119 3 548 554 10.1002/cncr.27782
65. Cheng D., Liang B., Li Y., Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One 2013 8 2 e55309
66. Trimbos J. B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., Vermorken J. B., Torri V., Mangioni C., Pecorelli S., International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003 95 2 105 112 2-s2.0-0037440207
67. McGuire W. P., Hoskins W. J., Brady M. F., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England Journal of Medicine 1996 334 1 6 10.1056/NEJM199601043340101
68. Muggia F. M., Braly P. S., Brady M. F., Sutton G., Niemann T. H., Lentz S. L., Alvarez R. D., Kucera P. R., Small J. M., Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2000 18 1 106 115 2-s2.0-0033986363
69. Ellis L. M., Hicklin D. J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 2008 8 8 579 591 2-s2.0-47949089077 10.1038/nrc2403
70. Raspollini M. R., Castiglione F., Garbini F., Villanucci A., Amunni G., Baroni G., Boddi V., Taddei G. L., Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. International Journal of Surgical Pathology 2005 13 2 135 142 2-s2.0-18144379214 10.1177/ 106689690501300202
71. Takano M., Kikuchi Y., Yaegashi N., Kuzuya K., Ueki M., Tsuda H., Suzuki M., Kigawa J., Takeuchi S., Tsuda H., Moriya T., Sugiyama T., Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. British Journal of Cancer 2006 94 10 1369 1374 2-s2.0-33646828032 10.1038/sj.bjc.6603116
72. du Bois A., Luck H. J., Meier W., A randomized cinic trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. The Journal of the National Cancer Institute 2003 95 1320 1329
73. Köbel M., Kalloger S. E., Carrick J., Huntsman D., Asad H., Oliva E., Ewanowich C. A., Soslow R. A., Gilks C. B., A limited Panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of theovary. American Journal of Surgical Pathology 2009 33 1 14 21 2-s2.0-59149101397 10.1097/PAS.0b013e3181788546
74. Lederman J. A., Marth C., Carey M. S., Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer 2011 21 4 763 770 10.1097/IGC.0b013e31821b2669
75. Foulkes W. D., BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Familial Cancer 2006 5 2 135 142 2-s2.0-33744760541 10.1007/s10689-005-2832-5
76. Bolton K. L., Chenevix-Trench G., Pharoah P. D., Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. The Journal of the American Medical Association 2012 307 4 382 390 10.1001/jama.2012.20
77. Yang D., Khan S., Sun Y., Hess K., Shmulevich I., Sood A. K., Zhang W., Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. The Journal of the American Medical Association 2011 306 14 1557 1565 2-s2.0-80053950209 10.1001/jama.2011.1456
78. Farmer H., McCabe H., Lord C. J., Tutt A. H. J., Johnson D. A., Richardson T. B., Santarosa M., Dillon K. J., Hickson I., Knights C., Martin N. M. B., Jackson S. P., Smith G. C. M., Ashworth A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 434 7035 917 921 2-s2.0-17244373777 10.1038/nature03445
79. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H. M., de Bono J. S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine 2009 361 2 123 134 2-s2.0-67650471685 10.1056/NEJMoa0900212
80. Ashworth A., A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology 2008 26 22 3785 3790 2-s2.0-49249119415 10.1200/JCO.2008.16.0812
81. Kaelin W. G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer 2005 5 9 689 698 2-s2.0-25444497278 10.1038/nrc1691
82. Audeh M. W., Carmichael J., Penson R. T., Friedlander M., Powell B., Bell-McGuinn K. M., Scott C., Weitzel J. N., Oaknin A., Loman N., Lu K., Schmutzler R. K., Matulonis U., Wickens M., Tutt A., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet 2010 376 9737 245 251 2-s2.0-77955039099 10.1016/S0140-6736(10)60893-8
83. Yap T. A., Sandhu S. K., Carden C. P., de Bono J. S., Poly (ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA: A Cancer Journal for Clinicians 2011 61 1 31 49 2-s2.0-79951821948 10.3322/caac.20095
84. Ang J., Yap T. A., Fong P. C., Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). Journal of Clinical Oncology 2010 28 15, supplement. abstract no. 5041
85. Kristjansdottir K., Dizon D., HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opinion on Biological Therapy 2010 10 2 243 250 2-s2.0-76149140525 10.1517/14712590903514090
86. Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003 21 2 283 290 2-s2.0-0037440042 10.1200/JCO.2003.10.104
87. Heublein S., Vrekoussis T., Mayr D., Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). Journal of Ovarian Research 2013 6 1, article 6 10.1186/1757-2215-6-6
88. Schwartz G. F., Hughes K. S., Lynch H. T., Fabian C. J., Fentiman I. S., Robson M. E., Domchek S. M., Hartmann L. C., Holland R., Winchester D. J., Anderson B. O., Arun B. K., Bartolink H., Bernard P., Bonanni B., Cady B., Clough K. B., Feig S. A., Heywang-Kobrunner S. H., Howell A., Isaacs C., Kopans D. B., Mansel R. E., Masood S., Palazzo J. P., Solin L. J., Untch M., Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 2008 113 10 2627 2637 2-s2.0-55849093873 10.1002/cncr.23903
89. Domchek S. M., Friebel T. M., Singer C. F., Gareth Evans D., Lynch H. T., Isaacs C., Garber J. E., Neuhausen S. L., Matloff E., Eeles R., Pichert G., Van T'veer L., Tung N., Weitzel J. N., Couch F. J., Rubinstein W. S., Ganz P. A., Daly M. B., Olopade O. I., Tomlinson G., Schildkraut J., Blum J. L., Rebbeck T. R., Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. The Journal of the American Medical Association 2010 304 9 967 975 2-s2.0-77956193440 10.1001/jama.2010.1237
90. Shuster L. T., Gostout B. S., Grossardt B. R., Rocca W. A., Prophylactic oophorectomy in premenopausal women and long-term health. Menopause International 2008 14 3 111 116 2-s2.0-56149101806 10.1258/mi.2008.008016
91. Turner N., Tutt A., Ashworth A., Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews Cancer 2004 4 10 814 819 2-s2.0-4944229642 10.1038/nrc1457
92. February 2013, http://www.cancer.gov/clinicaltrials